Shakti Pumps (India) Ltd, SMS Pharmaceuticals Ltd, Kopran Ltd and Shiva Mills Ltd are among the other losers in the BSE’s ‘B’ group today, 14 November 2022.

Chemcon Speciality Chemicals Ltd leads losers in ‘B’ group

North Eastern Carrying Corporation Ltd, Kamdhenu Ltd, Dodla Dairy Ltd and SMS Pharmaceuticals Ltd are among the other gainers in the BSE’s ‘B’ group today, 21 March 2022.

Selan Explorations Technology Ltd leads gainers in ‘B’ group

SMS Pharmaceuticals has received a non-exclusive license to manufacture and supply of nirmatrelvir through the Medicine Patent Pool to manufacture nirmatrelvir, an oral anti-viral Covid-19 medicine.

SMS Pharmaceuticals share price zooms after bagging licence to manufacture, supply oral COVID vaccines

SMS Pharmaceuticals jumped 13.1% to Rs 109.2 after the drug company received non exclusive license through medicines patent pool (MPP) to manufacture nirmatrelvir, an oral antiviral COVID-19 medicine developed by Pfizer.

SMS Pharma soars after receiving license to manufacture COVID-19 medicine

These include Cipla, Sun Pharma, Laurus Labs, Divi’s Laboratories, Glenmark, Emcure, Macleods, SMS Pharmaceuticals, Strides, Torrent, Cadila, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, and Viatris, among others.

19 Indian companies get licence to make Pfizer’s oral generic

More than 250 stocks touched their 52-week low, including Star Cement, SMS Pharmaceuticals, NBCC, LIC Housing Finance, HDFC Life Insurance Company and DCB Bank.

Taking Stock | Geopolitical tension roils market, indices see biggest single-day fall in nearly two years

SMS Pharmaceuticals consolidated net profit rises 109.94% in the September 2021 quarter

SMS Pharmaceuticals standalone net profit rises 152.17% in the June 2021 quarter

SMS Pharmaceuticals consolidated net profit rises 262.13% in the March 2021 quarter

SMS Pharmaceuticals standalone net profit rises 255.36% in the March 2021 quarter

The objective of the JV is to develop the products and manufacturing them at the company’s manufacturing facility. The technical ownership of the JV products will be the property of the JV Company
which includes Drug Mater Filings (DMFs) of the

SMS Pharmaceuticals incorporates JV company in Spain

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.